BeiGene, Ltd. (ONC) Stock Price

BeiGene, Ltd. Price

NYSE·CLOSED
411.29
​
Market closed

Revenue has compounded at 67.3% per year over the past 12 years to 5.34 B USD. BeiGene, Ltd.'s net margin stands at 5.4%, up from -123.9% several years earlier. Analysts set a median price target of 400.00 USD, implying 2.7% below the current price. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.

BeiGene, Ltd. stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BeiGene, Ltd. business model & stock analysis

BeiGene, Ltd. is a health care company based in Basel, Switzerland, operating globally with over 12,000 employees. It develops and commercializes innovative oncology treatments, including BRUKINSA for blood cancers, TEVIMBRA for solid tumors and blood cancers, SYLVANT for Castleman's disease, BAITUOWEI for breast cancer, and PARTRUVIX for solid tumors. The company also has multiple clinical-stage products targeting various cancer types through novel mechanisms of action.

Frequently asked questions about BeiGene, Ltd.

Analysts currently set an average price target of 400.67 USD for the BeiGene, Ltd. stock (median: 400.00 USD), implying -3.0 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the BeiGene, Ltd. stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BeiGene, Ltd. to generate revenue of 6.98 B USD and earnings per share of 7.41 USD.

Converted at the current exchange rate, the BeiGene, Ltd. share trades at 374.79 EUR (411.29 USD).

The expected revenue of BeiGene, Ltd. is 6.98 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BeiGene, Ltd. is 840.12 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BeiGene, Ltd. is currently 55.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BeiGene, Ltd. stock.

The price-to-sales ratio (P/S) of BeiGene, Ltd. is currently 6.69. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BeiGene, Ltd. stock.

The Eulerpool Quality Score for BeiGene, Ltd. is 6/10.

The ISIN of BeiGene, Ltd. is US07725L1026. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of BeiGene, Ltd. is ONC. The ticker symbol is used to trade BeiGene, Ltd. shares on the stock exchange.

Fair ValueTerminal
423.63 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
445,252.75 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Feb 3, 2016
ISIN
US07725L1026
Market capitalization
39.03 B USDLarge Cap
52-Week Range
PEG
9.73
P/E ratio
P/Ee 2026
46.46
P/Ee 2027
39.07
P/Ee 2028
30.01
P/Ee 2029
25.77
P/Ee 2030
21.45
P/S
P/Se
6.69
EV/EBIT
79.57
P/B Ratio
8.95
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
5.26 %
Last updated Nov 19, 2026, 7:10 AM

BeiGene, Ltd. Peer Group